<i>In Vitro</i> and <i>in Vivo</i> Antitrypanosomal Activitiy of Two Microbial Metabolites, KS-505a and Alazopeptin

Abstract

Our on-going screening program to discover new antitrypanosomal antibiotics has been evaluating compounds isolated from soil microorganisms as well as investigating the antibiotic libraries of the Kitasato Institute for Life Sciences and BioFrontier Laboratories of Kyowa Hakko Kogyo Co., Ltd. We have now discovered two compounds, KS-505a and alazopeptin, which exhibit moderate antitrypanosomal characteristics. We report here the in vitro and in vivo antitrypanosomal activities and cytotoxicities of KS-505a and alazopeptin, compared with some commonly-used antitrypanosomal drugs. This is the first report of in vitro and in vivo antitrypanosomal activities of either KS-505a or alazopeptin.

Citation

The Journal of Antibiotics (2008) 61 (10) 627–632 [doi:10.1038/ja.2008.83]

<i>In Vitro</i> and <i>in Vivo</i> Antitrypanosomal Activitiy of Two Microbial Metabolites, KS-505a and Alazopeptin

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.